Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

Kissei presents new series of D2 antagonists/5-HT4 agonists

July 11, 2001

Bayer HBV compound available for licensing worldwide

July 9, 2001

Aphios and ITC/Immune Technology to develop natural therapeutic for hepatitis C

July 6, 2001

Human fibroblast growth factor gene and use in cirrhosis and cancer

July 5, 2001

Company begins phase I evaluation of XTL-002 for treatment of HCV

July 4, 2001

Schering-Plough seeks FDA approval for new formulation of PEG-Intron

July 4, 2001

Roche licenses levovirin from ICN

July 3, 2001

Novirio establishes marketing agreement for LdT with Sumitomo

July 2, 2001

Adolor's opioid narcotic antagonist completes phase II trials for two indications

July 2, 2001

Agents for H. pylori infections designed by AstraZeneca to have improved stability

June 29, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...